Clinical trials: Eye
Dry Eye
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
This study will evaluate the safety and efficacy of SJP-0132 in Chinese Patients with Dry Eye. Patients will be randomly assigned to receive either SJP-0132 or placebo.
- Trial name
- NCT06717152
- Testing
- SJP-0132
- Where
- 35 sites in China
- Volunteers
- 427 people
- Sponsor
- Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.
Keratoconjunctivitis Sicca
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective…
- Trial name
- CVS (NCT00848198)
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- TearLab Corporation
Xerophthalmia
Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops
The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.
- Trial name
- NCT06263998
- Testing
- NCP112
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.
- Trial name
- NCT00758784
- Testing
- bromfenac ophthalmic solution 0.06%
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Bausch & Lomb Incorporated
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to: its individual components (Brinz and Brim), and the…
- Trial name
- NCT00961649
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 195 people
- Sponsor
- Alcon Research
Dry Eye, Dry Eye Syndrome of Unspecified Lacrimal Gland
Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.
Title of the study: Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic gel PRO-167 versus Corneregel®, on the ocular surface of ophthalmological and clinically healthy subjects.
- Trial name
- PRO-167/I (NCT03520348)
- Testing
- PRO-167, Corneregel
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Bacterial Conjunctivitis
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.
- Trial name
- NCT00759148
- Testing
- Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, Moxifloxacin AF Vehicle
- Volunteers
- 1,179 people
- Sponsor
- Alcon Research
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
The purpose of this study is: To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 To…
- Trial name
- NCT01521793
- Testing
- QLT091001
- Where
- 6 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- QLT Inc.
Dry Eye Disease
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT06493604
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Progressive Keratoconus
Corneal Collagen Cross-linking for Progressive Keratoconus
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
- Trial name
- CXL (NCT00647699)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Glaukos Corporation
Cataract
Clinical Evaluation of a New Viscoelastic for Cataract Surgery
The purpose of this study is to evaluate the safety and effectiveness of a new opthalmic viscoelastic material for the use in cataract surgery. The new viscoelastic will be compared to a currently marketed viscoelastic material.
- Trial name
- NCT00972621
- Testing
- Vitrax II, Viscoat
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Optics
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Neuromyelitis Optica Spectrum Disorder
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria.
- Trial name
- NCT01845584
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Myopia
Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses
The objective of this one month study is to evaluate the product performance of a redesigned PureVision Contact Lens compared to the PureVision Contact Lens when worn on a daily wear basis by wearers of contact lenses.
- Trial name
- NCT01118338
- Testing
- Redesigned Purevision Contact Lens, PureVision Contact Lens
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Bausch & Lomb Incorporated
Presbyopia
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
The purpose of this study was to assess the effect of topical UNR844-Cl (lipoic acid choline ester chloride) ophthalmic solution on near visual function in presbyopic subjects.
- Trial name
- NCT03809611
- Testing
- UNR844-Cl
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Cataracts
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
This is a prospective, single-center, single-arm, open-label, clinical study of the investigational TECNIS Symfony® Toric IOL. The study will enroll up to 100 subjects from a single investigative site in China.
- Trial name
- NCT05053399
- Testing
- Model Series ZXT
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Dry Eye Disease
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT06389214
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Geographic Atrophy
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related…
- Trial name
- NCT06161584
- Testing
- Pegcetacoplan
- Where
- 34 sites in United States
- Volunteers
- 300 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.